KRAS

News

Consortium hunts new KRAS drugs with fruit flies and AI

The launch of the first drugs to inhibit the cancer-related protein KRAS was a milestone moment in oncology, but their efficacy wanes over time and tumours can develop res

News

Angion stock falls after agreeing Elicio Therapeutics merger

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-sta

News

Mirati challenges Amgen with FDA okay for KRAS drug

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer.

News

Sanofi backs out of $500m cancer alliance with Revolution

Sanofi has walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as a combination with KRAS inhibitors, including Sanofi’s Mirati-par

News

Pharma M&A rumour mill grinds out Mirati's name again

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS

News

ESMO: Amgen reveals Lumakras data as rival looms in rear-vie...

Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in

Consortium hunts new KRAS drugs with fruit flies and AI

Angion stock falls after agreeing Elicio Therapeutics merger

Mirati challenges Amgen with FDA okay for KRAS drug

Sanofi backs out of $500m cancer alliance with Revolution

Pharma M&A rumour mill grinds out Mirati's name again

ESMO: Amgen reveals Lumakras data as rival looms in rear-vie...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

KRAS

Editor's Picks